UPDATE: Jefferies Raises PT to $10 on Amedisys, Maintains Neutral on Reimbursement Uncertainty
Jefferies maintained Amedisys (NASDAQ: AMED) with a Hold and raised the price target from $9.00 to $10.00.
Jefferies analyst Brian Tanquilut wrote, "We continue to have a cautious view on AMED given our belief that ongoing budget discussions in DC could yield incremental rate cuts for home nursing providers such as AMED. Additionally, we are concerned that ongoing volume pressure (from persistent weakness in recertifications) will impact AMED's ability to offset upcoming rate cuts and drive LT EPS growth."
Amedisys closed at $11.19 on Wednesday.
Latest Ratings for AMED
|Aug 2016||Mizuho Securities||Downgrades||Buy||Neutral|
|Jun 2016||Stephens & Co.||Initiates Coverage on||Equal-weight|
|Apr 2016||Obsidian Research Group||Downgrades||Market Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.